246 related articles for article (PubMed ID: 31811563)
1. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
Yildiz Celik S; Durmus H; Yilmaz V; Saruhan Direskeneli G; Gulsen Parman Y; Serdaroglu Oflazer P; Deymeer F
Acta Neurol Belg; 2020 Feb; 120(1):133-140. PubMed ID: 31811563
[TBL] [Abstract][Full Text] [Related]
2. Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis.
Uzawa A; Kawaguchi N; Kanai T; Himuro K; Oda F; Yoshida S; Yoshino I; Kuwabara S
J Neurol; 2015; 262(4):1019-23. PubMed ID: 25683765
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation.
Nagappa M; Mahadevan A; Gangadhar Y; Patil SA; Bokolia S; Bindu PS; Sinha S; Taly AB
Acta Neurol Scand; 2019 May; 139(5):428-437. PubMed ID: 30693486
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of late-onset myasthenia gravis.
Zivković SA; Clemens PR; Lacomis D
J Neurol; 2012 Oct; 259(10):2167-71. PubMed ID: 22476514
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
6. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
7. Antititin antibody in early- and late-onset myasthenia gravis.
Szczudlik P; Szyluk B; Lipowska M; Ryniewicz B; Kubiszewska J; Dutkiewicz M; Gilhus NE; Kostera-Pruszczyk A
Acta Neurol Scand; 2014 Oct; 130(4):229-33. PubMed ID: 24947881
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.
Deymeer F
Acta Myol; 2020 Dec; 39(4):345-352. PubMed ID: 33458590
[TBL] [Abstract][Full Text] [Related]
9. Late-onset myasthenia gravis is predisposed to become generalized in the elderly.
Sakai W; Matsui N; Ishida M; Furukawa T; Miyazaki Y; Fujita K; Miyamoto R; Yamamoto N; Sako W; Sato K; Kondo K; Nishida Y; Mitsui T; Izumi Y; Kaji R
eNeurologicalSci; 2016 Mar; 2():17-20. PubMed ID: 29473057
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
[TBL] [Abstract][Full Text] [Related]
11. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
Cordts I; Bodart N; Hartmann K; Karagiorgou K; Tzartos JS; Mei L; Reimann J; Van Damme P; Rivner MH; Vigneron A; Weis J; Schulz JB; Tzartos SJ; Claeys KG
J Neurol; 2017 Jun; 264(6):1193-1203. PubMed ID: 28516329
[TBL] [Abstract][Full Text] [Related]
12. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
13. A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.
Koneczny I; Mané-Damas M; Zong S; De Haas S; Huda S; van Kruining D; Damoiseaux J; De Rosa A; Maestri M; Guida M; Molenaar P; Van Damme P; Fichtenbaum A; Perkmann T; De Baets M; Lazaridis K; Zouvelou V; Tzartos S; Ricciardi R; Losen M; Martinez-Martinez P
Front Immunol; 2024; 15():1325171. PubMed ID: 38715598
[TBL] [Abstract][Full Text] [Related]
14. Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis.
Spagni G; Todi L; Monte G; Valentini M; Di Sante G; Damato V; Marino M; Evoli A; Lantieri F; Provenzano C
Ann Clin Transl Neurol; 2021 Mar; 8(3):656-665. PubMed ID: 33547763
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
16. Multiple antibody detection in 'seronegative' myasthenia gravis patients.
Hong Y; Zisimopoulou P; Trakas N; Karagiorgou K; Stergiou C; Skeie GO; Hao HJ; Gao X; Owe JF; Zhang X; Yue YX; Romi F; Wang Q; Li HF; Gilhus NE; Tzartos SJ
Eur J Neurol; 2017 Jun; 24(6):844-850. PubMed ID: 28470860
[TBL] [Abstract][Full Text] [Related]
17. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
18. A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis.
Ponseti JM; Caritg N; Gamez J; López-Cano M; Vilallonga R; Armengol M
Expert Opin Biol Ther; 2009 Jan; 9(1):1-8. PubMed ID: 19063688
[TBL] [Abstract][Full Text] [Related]
19. Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis.
Romi F; Gilhus NE; Varhaug JE; Myking A; Skeie GO; Aarli JA
Ann N Y Acad Sci; 2003 Sep; 998():481-90. PubMed ID: 14592917
[TBL] [Abstract][Full Text] [Related]
20. Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.
Stergiou C; Lazaridis K; Zouvelou V; Tzartos J; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Behin A; Sharshar T; De Baets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Gilhus NE; Casasnovas Pons C; Pitha J; Jakubíkova M; Hanisch F; Bogomolovas J; Labeit D; Labeit S; Tzartos SJ
J Neuroimmunol; 2016 Mar; 292():108-15. PubMed ID: 26943968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
